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From FABIO PARAZZINI,* ALLAN HILDESHEIM,*# MONICA FERRARONl.t CARLO LA
VECCHIA** AND LOUISE BRINTON*
Sir—We thank Gefeller and Windeler for their careful
review1 of our article on relative and attributable risk
for cervical cancer in the US and Italy,2 and welcome
the opportunity to address some of the main issues
they raise.
Gefeller and Windeler criticize the lack of precise
definitions for the variables used in calculating attri-
butable risk (AR) estimates and the use of the AR
rather than the preventive fraction (PF) to estimate the
impact of screening on the incidence of cervical cancer.
We agree that it is important to define the exposures
for which ARs were estimated. It is particularly im-
portant that the baseline, or unexposed, level be de-
fined given the sensitivity of the AR estimates to such a
choice. For all exposures examined, with the exception
of Pap smear screening, the exposures used in cal-
culating AR estimates were identical to the variables
defined in Tables 2 and 3. For Pap smear screening, we
collapsed 'number of Pap smears' and 'time since last
Pap smear' from Table 4 into one AR estimate. Thus,
the baseline level for the variable 'inadequate Pap
screening' in Table 5 is three or more Pap smears in the
past 10 years and less than 2 years since the last Pap
smear (excluding diagnostic Paps for cases).
With respect to Gefeller and Windeler's comment
that PF rather than AR estimates should be used for
screening, we have opted to utilize the AR to estimate
the effect of screening. This was done for consistency,
since the AR is used for the remaining exposures
presented in the table. We believe that this should not
hamper the readers' interpretation of the results since,
as conceded by Gefeller and Windeler, the PF and AR
are highly related measures.
Gefeller and Windeler suggest that 95% confidence
intervals around the AR estimates would assist readers
in interpreting the findings presented in our article. To
this end, they refer us to an article by Greenland.3 The
method described by Greenland, however, applies only
to dichotomous variables and all but one of the
variables used in our analysis were polychotomous.
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More relevant to the aims of our study is a recent
report by Benichou and Gail4 which describes the
theory for calculating the variance for the AR esti-
mates computed using Bruzzi's method.5 Benichou
and Gail mention that they are in the process of
developing a computer program to implement these
methods. We agree with Gefeller and Windeler that
future studies which utilize AR estimates should at-
tempt to incorporate a method of variance estimation.
Gefeller and Windeler criticize our interpretation of
the findings presented in Table 5. They suggest that
our discussion is overly optimistic in assuming that
90-95% of cervical cancer is explained by the factors
examined and that lack of screening accounts for as
much as 45% of invasive cervical cancer cases in the
US and 85% in Italy. As we previously discussed in the
methods section of our paper, we agree that AR
estimates are not additive. However, recognizing the
limitations of AR estimates,6'7 we chose to present the
AR statistic to highlight the potential importance of
screening in preventing invasive cervical cancer.
Despite the higher prevalence in the US of exposure to
the risk factors examined, the rate of cervical cancer is
higher in Italy. Our use of the AR was an attempt to
emphasize the potentially important role Pap smear
screening can play in reducing the incidence of cervical
cancer. Perhaps we should have been more careful in
stating that the risk factors examined explain in part
90-95% of invasive cervical cancers diagnosed in the
US and Italy, implying that removal of all five risk fac-
tors examined and implementation of screening would
not necessarily reduce the incidence of invasive cervical
cancer by this amount. Similarly, we might have stated
that 45% of invasive cervical cancer in the US and
85% in Italy is attributable, in part, to inadequate
screening practices.
Gefeller and Windeler also criticize the use of case-
control studies in evaluating screening programmes.
Although it is true that a randomized prospective trial
has intuitive appeal, its use to evaluate cervical can-
cer screening would be unethical. Non-experimental
approaches must therefore be utilized to evaluate the
efficacy of Pap smear screening. We do not feel that a
detailed discussion of the advantages and limitations
of utilizing case-control studies to evaluate screening
programmes is warranted, given the wide amount of
literature already available on this subject. We direct
Gefeller and Windeler as well as other interested
readers to reviews by Sasco et a/,8 Morrison,9and Cole
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and Morrison. l0To quote from Sasco et al, 'The typical
situation where a case-control evaluation of screening
might be the method of choice is when a large number
of screening tests have been performed over a period
of years, or even decades, but no proper controlled
evaluation has been undertaken. Cancer of the cervix
is one obvious example. . . .'
Finally, we would like to note a few comments made
by Gefeller and Windeler which might be misinter-
preted by readers. First, Gefeller and Windeler imply
that lead time bias would result in an overly optimistic
estimate of the benefit of screening measures. If
anything, lead time bias tends to underestimate the
benefit of screening programmes by including as cases
individuals who were screen-detected.9 Second,
Gefeller and Windeler imply that AR estimates should
be used only for causal factors. Although this is
generally the case, we believe that AR estimates are
useful in interpreting the effectiveness of Pap smear
screening in preventing invasive cancer, despite the
lack of a causal relationship between screening and
cervical cancer. Third, Gefeller and Windeler imply
that confounding could account for our finding of a
protective effect of screening. Although residual con-
founding is always a possibility in any observational
study, we would like to point out that the risk
estimates used in obtaining ARs were adjusted for
potential confounding by several factors. Notably, our
estimate of risk associated with lack of screening was
controlled for potential confounding by age, educa-
tion, parity, number of sexual partners, age at first
intercourse, oral contraceptive use, and smoking.
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Validity of Case-Control Studies and Randomized Controlled Trials
of Screening.
From ANNIE J SASCO*
Sir—More and more often in epidemiological
literature, we come across papers and comments
emphasizing the notion that case-control studies of
screening are biased.1 This statement usually derives
from the comparison of results of case-control
studies with those of randomized controlled trials
(RCT). My contention is that a direct comparison is
not meaningful and should not be attempted. In my
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opinion, it is of the utmost importance to keep in
mind that these two types of study measure a different
effect.
RCT of screening measure the incidence rate of dis-
ease or the mortality rate in two groups of subjects,
one having been randomly allocated to a screening
programme and the other not. We therefore have
absolute rates of occurrence for the two groups and we
can compare them by means of a difference or a ratio
of incidence or mortality rates. In the context of RCT,
everyone in the group randomized to screening has
been offered screening, whereas those in the control
group have not. Of course, some of the members of
the screening group may refuse to be screened, thereby
